Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC disclosures from a clinical-stage biotech like Arcellx can stretch hundreds of pages packed with trial protocols, cash-burn tables, and FDA correspondence. Locating the exact cash-runway figure or deciphering an Arcellx annual report 10-K simplified often demands specialist knowledge and hours of scrolling.
Stock Titan removes that friction. Our AI reads every document the moment it lands on EDGAR, turning raw text into plain-language highlights. Open an Arcellx quarterly earnings report 10-Q filing to see R&D spend, enrollment numbers, and liquidity ratios summarized in seconds. Each Arcellx 8-K material events explained module pinpoints trial pauses, new partnerships, or financing rounds, while Arcellx insider trading Form 4 transactions appear in real time so you can track sentiment. Need deeper context? Trend graphs group every Arcellx executive stock transactions Form 4 and flag unusual activity.
The page goes beyond surface data. Our earnings report filing analysis compares sequential R&D trends, and the Arcellx proxy statement executive compensation section links leadership pay to pipeline milestones. Toggle from AI commentary to the source file with one click—perfect for understanding Arcellx SEC documents with AI while keeping primary evidence close. Whether you’re scanning Arcellx Form 4 insider transactions real-time before a trade or need Arcellx SEC filings explained simply for diligence, this hub delivers comprehensive coverage and insight you can act on.
Arcellx, Inc. reported Q3 2025 results. Collaboration revenue was $4.9 million, down from $26.0 million a year ago as iMMagine-1 dosing and manufacturing wound down. The company posted a net loss of $55.8 million (basic and diluted $(0.99) per share) versus a $25.9 million loss last year.
Operating expenses rose to $66.7 million, with R&D $35.1 million (lower on reduced anito-cel trial activity) and G&A $31.6 million (higher commercial readiness and personnel costs). Other income was $6.0 million on interest.
Liquidity remained solid with $576.0 million in cash, cash equivalents and marketable securities at quarter-end, and management believes this funds operations into 2028. Contract liabilities to the Kite collaboration totaled $112.2 million. Year-to-date, Arcellx raised $131.6 million via its at-the-market program (1,905,715 shares). As of October 31, 2025, shares outstanding were 57,822,871. The company continues co-development of anito-cel with Kite, including the global Phase 3 iMMagine-3 in multiple myeloma.
Arcellx, Inc. furnished a current report on Form 8-K to announce that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. The report lists ACLX as the trading symbol on The Nasdaq Stock Market LLC and is signed by Chief Executive Officer Rami Elghandour on November 5, 2025.
Arcellx (ACLX) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO sold 5,364 shares of common stock at a weighted average price of $91.0357, with trades ranging from $90.99 to $91.19, under a Rule 10b5-1 trading plan entered on March 21, 2025.
Following the sale, the officer beneficially owns 8,466 shares, held directly.
Arcellx (ACLX) reported insider activity by its Chief Financial Officer. On 10/03/2025, the CFO sold 4,882 shares of common stock at a weighted average price of $86.0036. On 10/06/2025, the CFO sold an additional 1,064 shares at a weighted average price of $86.2155. These sales were made under a Rule 10b5-1 trading plan entered on March 21, 2025. Following the transactions, the officer directly beneficially owned 13,830 shares.
ACLX: A Form 144 notice indicates a planned sale of up to 5,946 shares of common stock with an aggregate market value of $488,999.04. The shares are listed on NASDAQ and the sale is approximately dated October 3, 2025, with Morgan Stanley Smith Barney LLC named as broker.
The securities were acquired as Restricted Stock Units on January 3, 2025. The filing lists 55,458,912 shares outstanding as context.
Arcellx insider sales disclosed on Form 4: Christopher Heery, identified as a director and Chief Medical Officer, reported multiple sales of Arcellx common stock on 09/30/2025 executed under a Rule 10b5-1 trading plan established on March 23, 2025. The filings show three sale transactions totaling 21,034 shares — 5,300 shares at a weighted average price of $80.5518, 14,204 shares at a weighted average price of $81.4584, and 1,530 shares at a weighted average price of $82.198. Following those reported transactions the Form lists beneficial ownership amounts of 16,358, 2,154, and 624 shares on the respective lines. The Form 4 is signed and dated 09/30/2025.
Arcellx insider sale disclosed: Chief Medical Officer Christopher Heery reported a sale of 73 shares of Arcellx common stock on 09/29/2025 at $80.16 per share, leaving him with 21,658 shares held directly. The filing states the sale was executed under a Rule 10b5-1 trading plan established on March 23, 2025, indicating the transaction followed a prearranged compliance program.
This disclosure is a routine insider disposition that documents the number of shares sold, the price, and the resulting direct ownership stake; no derivative transactions or other material changes in ownership are reported.
Arcellx insider sale under 10b5-1 plan. The chief medical officer sold 12,396 shares of Arcellx common stock under a Rule 10b5-1 trading plan, at a weighted average price of $80.119 per share, and now beneficially owns 21,731 shares. The filing reports the transaction as a sale and identifies the sale price range as $80.00 to $80.41 with the weighted average disclosed. The reporting person indicates the sale was pre-arranged under a March 23, 2025 10b5-1 plan and offers to provide breakdown by price on request.
Heery Christopher, Chief Medical Officer of Arcellx, Inc. (ACLX), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/18/2025 he sold 3,343 shares at a weighted average price of $80.0085, leaving him with 34,427 shares beneficially owned after that transaction. On 09/19/2025 he sold an additional 300 shares at $80.00, leaving 34,127 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
The filing notes the sales were effected pursuant to a 10b5-1 plan entered March 23, 2025, and that the post-transaction totals include 284 shares acquired under the issuer's 2022 Employee Stock Purchase Plan on May 14, 2025. No derivative transactions or other changes were reported.
Arcellx, Inc. (ACLX) filed a Form 144 notifying the proposed sale of 37,486 common shares through Morgan Stanley Smith Barney on 09/18/2025 with an aggregate market value of $2,864,680.12. The filing lists total shares outstanding as 55,458,912, meaning the proposed sale equals approximately 0.0676% of outstanding shares. The securities being offered were acquired through three routes: restricted stock units granted on 01/02/2025 (28,208 shares), participation in an employee stock purchase plan on 05/12/2023 (1,483 shares), and previously exercised stock options on 09/03/2024 (7,795 shares). No securities were reported sold in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
FAQ
What is the current stock price of ARCELLX (ACLX)?
What is the market cap of ARCELLX (ACLX)?
